Article
Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2022
Nagasaka Misako, Balmanoukian Ani S, Madison Russell, Zhang Shannon S, Klempner Samuel J, Ou Sai-Hong Ignatius
Abstract excerpt
The sequential use of 1st-/2nd-generation to 3rd-generation epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) has led to the emergence of triple EGFR mutations generally consisting of the founder mutation (del 19 or L858R), gatekeeper mutation (T790M) and mutation (C797S) that abolishes the covalent binding of osimertinib to the EGFR protein (i.e., del 19 or L858R/T790M/C797S). Besides C797S, other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.